NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics,
Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star Bulk Carriers Corp. (NASDAQ:SBLK), AngioDynamics, Inc. (NASDAQ:ANGO), Marinus
Pharmaceuticals, Inc. (NASDAQ:MRNS), and Advaxis, Inc. (NASDAQ:ADXS), including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
HRTX DOWNLOAD: http://Fundamental-Markets.com/register/?so=HRTX
IDA DOWNLOAD: http://Fundamental-Markets.com/register/?so=IDA
SBLK DOWNLOAD: http://Fundamental-Markets.com/register/?so=SBLK
ANGO DOWNLOAD: http://Fundamental-Markets.com/register/?so=ANGO
MRNS DOWNLOAD: http://Fundamental-Markets.com/register/?so=MRNS
ADXS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADXS
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Heron
Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star Bulk Carriers Corp. (NASDAQ:SBLK), AngioDynamics, Inc.
(NASDAQ:ANGO), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Advaxis, Inc. (NASDAQ:ADXS) on a fundamental level and outlines the
overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone
summaries and as such, important information may be missing from these samples. Please download the entire research report, free of
charge, to ensure you are reading all relevant material information. All information in this release was accessed January 28th,
2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
HERON THERAPEUTICS, INC. (HRTX) REPORT OVERVIEW
Heron Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Heron Therapeutics reported revenue of
$19.79MM vs $8.57MM (up 130.82%) and analysts estimated basic earnings per share -$0.49 vs -$0.77. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Heron Therapeutics reported revenue of $30.77MM vs $1.28MM (up 2,305.55%) and analysts
estimated basic earnings per share -$3.65 vs -$4.56. Analysts expect earnings to be released on February 26th, 2019. The report
will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$1.09. The estimated
EPS forecast for the next fiscal year is -$1.02 and is expected to report on February 26th, 2019.
To read the full Heron Therapeutics, Inc. (HRTX) report, download it here: http://Fundamental-Markets.com/register/?so=HRTX
-----------------------------------------
IDACORP, INC. (IDA) REPORT OVERVIEW
IDACORP's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, IDACORP reported revenue of $408.80MM
vs $408.32MM (up 0.12%) and analysts estimated basic earnings per share $2.03 vs $1.80 (up 12.78%). For the twelve months ended
December 31st, 2017 vs December 31st, 2016, IDACORP reported revenue of $1,349.49MM vs $1,262.02MM (up 6.93%) and analysts
estimated basic earnings per share $4.22 vs $3.94 (up 7.11%). Analysts expect earnings to be released on February 21st, 2019. The
report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.77. The
estimated EPS forecast for the next fiscal year is $4.42 and is expected to report on February 21st, 2019.
To read the full IDACORP, Inc. (IDA) report, download it here: http://Fundamental-Markets.com/register/?so=IDA
-----------------------------------------
STAR BULK CARRIERS CORP. (SBLK) REPORT OVERVIEW
Star Bulk Carriers' Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Star Bulk Carriers reported revenue of
$121.06MM vs $64.87MM (up 86.63%) and analysts estimated basic earnings per share $0.15 vs -$0.26. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Star Bulk Carriers reported revenue of $331.98MM vs $222.11MM (up 49.47%) and analysts
estimated basic earnings per share -$0.16 vs -$3.24. Analysts expect earnings to be released on February 26th, 2019. The report
will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.33. The estimated EPS
forecast for the next fiscal year is $1.08 and is expected to report on February 26th, 2019.
To read the full Star Bulk Carriers Corp. (SBLK) report, download it here: http://Fundamental-Markets.com/register/?so=SBLK
-----------------------------------------
ANGIODYNAMICS, INC. (ANGO) REPORT OVERVIEW
AngioDynamics' Recent Financial Performance
For the three months ended November 30th, 2018 vs November 30th, 2017, AngioDynamics reported revenue of
$91.50MM vs $86.71MM (up 5.53%) and basic earnings per share $0.06 vs $0.01 (up 500.00%). For the twelve months ended May 31st,
2018 vs May 31st, 2017, AngioDynamics reported revenue of $344.29MM vs $349.64MM (down 1.53%) and analysts estimated basic earnings
per share $0.44 vs $0.14 (up 214.29%). Analysts expect earnings to be released on April 4th, 2019. The report will be for the
fiscal period ending February 28th, 2019. The reported EPS for the same quarter last year was $0.25. The estimated EPS forecast for
the next fiscal year is $0.97 and is expected to report on July 10th, 2019.
To read the full AngioDynamics, Inc. (ANGO) report, download it here: http://Fundamental-Markets.com/register/?so=ANGO
-----------------------------------------
MARINUS PHARMACEUTICALS, INC. (MRNS) REPORT OVERVIEW
Marinus Pharmaceuticals' Recent Financial Performance
Analysts expect earnings to be released on March 5th, 2019. The report will be for the fiscal period ending
December 31st, 2018. The reported EPS for the same quarter last year was -$0.20. The estimated EPS forecast for the next fiscal
year is -$1.05 and is expected to report on March 5th, 2019.
To read the full Marinus Pharmaceuticals, Inc. (MRNS) report, download it here: http://Fundamental-Markets.com/register/?so=MRNS
-----------------------------------------
ADVAXIS, INC. (ADXS) REPORT OVERVIEW
Advaxis' Recent Financial Performance
For the three months ended October 31st, 2018 vs October 31st, 2017, Advaxis reported revenue of $1.13MM vs
$1.76MM (down 35.96%) and analysts estimated basic earnings per share -$0.26 vs -$0.57. For the twelve months ended October 31st,
2018 vs October 31st, 2017, Advaxis reported revenue of $6.06MM vs $12.03MM (down 49.61%) and analysts estimated basic earnings per
share -$1.29 vs -$2.31. Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period
ending January 31st, 2019. The reported EPS for the same quarter last year was -$0.49. The estimated EPS forecast for the next
fiscal year is -$0.35 and is expected to report on January 9th, 2020.
To read the full Advaxis, Inc. (ADXS) report, download it here: http://Fundamental-Markets.com/register/?so=ADXS
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading
brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals
worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA®
BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst®
(CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit
firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail
at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental
Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result
from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the
material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the
publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm,
investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full
disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
